Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
23andMe Holding Co. (commonly known as 23andMe) is a publicly held personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing direct-to-consumer genetic testing services. Customers provide a saliva sample, which is laboratory-analyzed to generate reports relating to ancestry, genetic health risks, carrier status for certain conditions, and predicted traits. Beyond individual insights, 23andMe leverages de-identified, aggregated genetic data from consenting customers for research purposes, aiming to make discoveries about diseases and traits, and to develop new therapeutics through its therapeutics division. The company's mission is to help people access, understand, and benefit from the human genome.
The headquarters serves as the primary center for research and development, corporate strategy, product innovation, engineering, data science, and administrative operations.
The facility is a modern office and lab space designed to foster collaboration and scientific discovery, equipped with advanced genomics research capabilities.
23andMe cultivates a mission-driven work environment characterized by innovation, scientific rigor, and a focus on empowering individuals with genetic information. Employees often share a passion for science, health, and technology.
Its location in the Bay Area provides strategic access to a rich talent pool, leading research institutions, and venture capital, crucial for a company at the forefront of biotechnology and consumer genetics.
While its physical operations and headquarters are based in the United States, 23andMe offers its direct-to-consumer genetic testing services to customers in numerous countries across North America, Europe, and other regions. Its research initiatives benefit from a diverse, global customer base that consents to participate, enabling broad genetic studies. Customer support and logistics are managed to serve this international clientele, although core research and development are centralized in the US.
349 Oyster Point Blvd
South San Francisco
CA
USA
Address: 223 N Mathilda Ave, Sunnyvale, CA 94086 (This was a former primary location; current operational status as a distinct major office is less emphasized after consolidation to South San Francisco. May house specific teams or legacy operations).
To support specific operational or research needs that may not be fully consolidated into the main HQ, or as a legacy site.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Genetics' leadership includes:
Genetics has been backed by several prominent investors over the years, including:
In the past 12 months, 23andMe saw a key transition in its finance leadership with the departure of its CFO and the appointment of an interim CFO. The company also underwent restructuring, including layoffs, though specific C-suite impacts beyond finance were not widely publicized as direct departures.
Discover the tools Genetics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Understanding common email formats at 23andMe can be useful for professional communication. Like many tech and biotech companies, 23andMe likely follows a standard pattern for its corporate email addresses.
A common format is [first_initial][last]@23andme.com (e.g., jsmith@23andme.com). Another possibility is [first].[last]@23andme.com (e.g., john.smith@23andme.com).
Format
awojcicki@23andme.com
Example
80%
Success rate
Fierce Biotech • February 29, 2024
23andMe conducted another round of layoffs, reducing its workforce by approximately 71 employees, primarily impacting its therapeutics division, as part of cost-cutting measures....more
23andMe Investor Relations • February 7, 2024
23andMe announced its financial results for the third quarter of fiscal year 2024, detailing revenue, expenses, and progress in its consumer and therapeutics businesses....more
FDA • December 5, 2023
The FDA granted 23andMe authorization for a direct-to-consumer genetic test for a variant in the CYP2C19 gene, which can impact how the body metabolizes certain medications, including clopidogrel....more
23andMe Investor Relations • November 9, 2023
23andMe announced that Steven Schoch would step down as Chief Financial Officer, and Joseph R. Selsavage was appointed as Interim Chief Financial and Accounting Officer, effective November 13, 2023....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Genetics, are just a search away.